An initiative of Flandersbio

Listed companies

Listed companies

in english

The combined market cap of Belgian SME biotech companies gained top position in the European ranking. The fact that the number of qualifying companies is 2 to 3 times smaller than in other European countries confirms the intrinsic quality of the Belgian public biotech sector.


UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

UCB on


Chart IPO Statistics Pipeline Contact

Click on the chart to follow the daily exchange rate.

View the NYSE Euronext chart

  • Listing date:   01/1928 (Foundation of Union Chimique Belge)

View chart De Tijd

Product Indications and progress Partner
Neupro® CNS - advanced Parkinson's disease (US)
Neupro® CNS - restless legs syndrome (US)
Xyrem® CNS - fibromyalgia (EU)
Vimpat® CNS - epilepsy - monotherapy (US)
brivaracetam CNS - epilepsy - adjunctive therapy
Vimpat® CNS - epilepsy - monotherapy (EU)
Vimpat® CNS - epilepsy - adjunctive therapy
Vimpat® CNS - epilepsy - adjunctive therapy PGTC
UCB 2892 CNS - cognitive disorders
Cimzia® Immunology - ankylosing spondylitis
Cimzia® Immunology - psoriatic arthritis
Cimzia® Immunology - theumatoid arthritis (Japan)
Cimzia® Immunology - juvenile rheumatoid arthritis
epratuzumab Immunology - systemic lupus erythematosus
CDP7851 Immunology - fracture healing
CDP7851 Immunology - post-menopusal osteoporosis
CDP7851 Immunology - auto-immune disease
CDP7851 Immunology - systemic lupus erythematosus

Investor Relations:
Address details:
Allée de la Recherche 60, 1070 Brussels, Belgium

Back to top